RxDoctor Payments Data

Karli May

Nurse Practitioner · Mount Pleasant, TXNPI 1346976453

Payments from drug & device makers

$955in general payments, 2019–2025

Across 24 payments — averaging $39.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$597
  • Astellas Pharma US Inc$114
  • 180 Medical, Inc.$100
  • Dendreon Pharmaceuticals LLC$33
  • Bioprotect Medical, Inc.$23
  • Endo USA, Inc.$19
  • plus $68 from 4 others

What the payments were for

  • Travel & lodging$38440%
  • Food & beverage$47750%
  • Education$9410%

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teleflex LLC10$597
Astellas Pharma US Inc2$114
180 Medical, Inc.5$100
Dendreon Pharmaceuticals LLC1$33
Bioprotect Medical, Inc.1$23
Endo USA, Inc.1$19
Civco Medical Instruments1$18
Procept Biorobotics Corporation1$18
Pfizer1$17
Coloplast1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$955 in reported general payments places this provider in the 75th percentile of 5,422 nurse practitioner providers in Texas.

See all nurse practitioner providers in Texas

Medicare billing

Part B allowed, 2024
$124,860
Medicare patients
520
Services billed
1,878

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron144$87,601
MyrbetriqMirabegron111$65,223
Tamsulosin Hcl442$5,030
Methenamine Hippurate31$2,773
Silodosin26$2,424
Potassium Citrate ErPotassium Citrate17$1,338
Testosterone Cypionate29$1,096
Testosterone16$965
Finasteride44$581
Tadalafil19$511
Cefpodoxime Proxetil23$447
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$389
Alfuzosin Hcl ErAlfuzosin Hcl21$377
CefuroximeCefuroxime Axetil12$224
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim52$210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$114$65,223111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,422 nurse practitioner providers in Texas.

Other nurse practitioner in Mount Pleasant

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →